Pulmatrix, Inc. (PULM) News
Filter PULM News Items
PULM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PULM News From Around the Web
Below are the latest news stories about PULMATRIX INC that investors may wish to consider to help them evaluate PULM as an investment opportunity.
Pulmatrix and Cullgen Announce Proposed MergerPulmatrix, Inc. ("Pulmatrix") (Nasdaq: PULM), a clinical-stage biopharmaceutical company, today announced a merger agreement with Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of target |
Pulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)Pulmatrix ( NASDAQ:PULM ) Third Quarter 2024 Results Key Financial Results Revenue: US$366.0k (down 79% from 3Q 2023... |
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical assets. |
Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)Pulmatrix ( NASDAQ:PULM ) Second Quarter 2024 Results Key Financial Results Revenue: US$1.55m (down 16% from 2Q 2023... |
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets. |
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationPulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD). |
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced publication of, "Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, d |
Pulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)Pulmatrix ( NASDAQ:PULM ) First Quarter 2024 Results Key Financial Results Revenue: US$5.89m (up 293% from 1Q 2023... |
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdatePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced first quarter financial results for 2024 and provided a corporate update on its development programs. |
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate UpdatePulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs. |